These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30117017)

  • 1. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Xia C; Labotka R; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2019 Apr; 58(4):431-449. PubMed ID: 30117017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
    Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
    J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
    Gupta N; Diderichsen PM; Hanley MJ; Berg D; van de Velde H; Harvey RD; Venkatakrishnan K
    Clin Pharmacokinet; 2017 Nov; 56(11):1355-1368. PubMed ID: 28290121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological characteristics and clinical study results of the oral proteasome inhibitor ixazomib (NINLARO
    Machida M; Fukunaga S; Hara T
    Nihon Yakurigaku Zasshi; 2018; 151(4):166-178. PubMed ID: 29628465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixazomib - the first oral proteasome inhibitor.
    Xie J; Wan N; Liang Z; Zhang T; Jiang J
    Leuk Lymphoma; 2019 Mar; 60(3):610-618. PubMed ID: 30614337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses.
    Gupta N; Yang H; Hanley MJ; Zhang S; Liu R; Kumar S; Richardson PG; Skacel T; Venkatakrishnan K
    Target Oncol; 2017 Oct; 12(5):643-654. PubMed ID: 28803351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
    Gupta N; Hanley MJ; Venkatakrishnan K; Perez R; Norris RE; Nemunaitis J; Yang H; Qian MG; Falchook G; Labotka R; Fu S
    Br J Clin Pharmacol; 2016 Sep; 82(3):728-38. PubMed ID: 27121262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Hanley MJ; Gupta N; Venkatakrishnan K; Bessudo A; Sharma S; O'Neil BH; Wang B; van de Velde H; Nemunaitis J
    J Clin Pharmacol; 2018 Jan; 58(1):114-121. PubMed ID: 28783865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
    Smith DC; Kalebic T; Infante JR; Siu LL; Sullivan D; Vlahovic G; Kauh JS; Gao F; Berger AJ; Tirrell S; Gupta N; Di Bacco A; Berg D; Liu G; Lin J; Hui AM; Thompson JA
    Invest New Drugs; 2015 Jun; 33(3):652-63. PubMed ID: 25777468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.
    Gupta N; Zhao Y; Hui AM; Esseltine DL; Venkatakrishnan K
    Br J Clin Pharmacol; 2015 May; 79(5):789-800. PubMed ID: 25377318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma.
    Gupta N; Hanley MJ; Venkatakrishnan K; Wang B; Sharma S; Bessudo A; Hui AM; Nemunaitis J
    J Clin Pharmacol; 2016 Oct; 56(10):1288-95. PubMed ID: 26872892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
    Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
    Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients.
    Gupta N; Huh Y; Hutmacher MM; Ottinger S; Hui AM; Venkatakrishnan K
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):507-16. PubMed ID: 26141494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
    Gupta N; Goh YT; Min CK; Lee JH; Kim K; Wong RS; Chim CS; Hanley MJ; Yang H; Venkatakrishnan K; Hui AM; Esseltine DL; Chng WJ
    J Hematol Oncol; 2015 Sep; 8():103. PubMed ID: 26337806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
    Gupta N; Hanley MJ; Diderichsen PM; Yang H; Ke A; Teng Z; Labotka R; Berg D; Patel C; Liu G; van de Velde H; Venkatakrishnan K
    Clin Pharmacol Ther; 2019 Feb; 105(2):376-387. PubMed ID: 29446068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis.
    Gupta N; Hanley MJ; Harvey RD; Badros A; Lipe B; Kukreti V; Berdeja J; Yang H; Hui AM; Qian M; Zhang X; Venkatakrishnan K; Chari A
    Br J Haematol; 2016 Sep; 174(5):748-59. PubMed ID: 27196567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
    Richardson PG; Baz R; Wang M; Jakubowiak AJ; Laubach JP; Harvey RD; Talpaz M; Berg D; Liu G; Yu J; Gupta N; Di Bacco A; Hui AM; Lonial S
    Blood; 2014 Aug; 124(7):1038-46. PubMed ID: 24920586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders.
    Smolewski P; Rydygier D
    Expert Opin Investig Drugs; 2019 May; 28(5):421-433. PubMed ID: 30907163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.